Search

Author/Creator Armstrong, April

1. Biosimilars in Dermatology: Analytical, Regulatory, and Clinical Considerations: A Treatise From the Medical Board of the National Psoriasis Foundation. Issue 3 (July 2019)

Authors:
Yamauchi, Paul S.; Sachsman, Suzanne M.; Wu, Jashin J.; Siegel, Michael; Van Voorhees, Abby; Armstrong, April; Kay, Jonathan
Journal:
Journal of psoriasis and psoriatic arthritis
Issue:
Volume 4:Issue 3(2019)
Page Start:
125
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Comparative cost-effectiveness of tildrakizumab and other commonly used treatments for moderate-to-severe psoriasis. (3rd October 2021)

Authors:
Wu, Jashin J.; Jia, Xiaoying; Zhao, Yang; Carrico, Justin; Brodtkorb, Thor-Henrik; Mendelsohn, Alan; Lowry, Simon; Feldman, Steven R.; Armstrong, April
Journal:
Journal of dermatological treatment
Issue:
Volume 32:Number 7(2021)
Page Start:
693
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders. (3rd October 2022)

Authors:
Strober, Bruce; Armstrong, April; Rubant, Simone; Patel, Manish; Wu, Tianshuang; Photowala, Huzefa; Crowley, Jeffrey
Journal:
Journal of dermatological treatment
Issue:
Volume 33:Number 7(2022)
Page Start:
2991
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Issue 10273 (6th February 2021)

Authors:
Reich, Kristian; Papp, Kim A; Blauvelt, Andrew; Langley, Richard G; Armstrong, April; Warren, Richard B; Gordon, Kenneth B; Merola, Joseph F; Okubo, Yukari; Madden, Cynthia; Wang, Maggie; Cioffi, Christopher; Vanvoorden, Veerle; Lebwohl, Mark
Journal:
Lancet
Issue:
Volume 397:Issue 10273(2021)
Page Start:
487
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. The global challenge for skin health. (1st June 2015)

Authors:
Hay, R.J.; Augustin, M.; Griffiths, C.E.M.; Sterry, W.; Abuabara, Katrina; Airoldi, Mara; Ajose, Frances; Albert, Sandra; Armstrong, April; Asgari, Maryam; Bevan, Gwyn; Blume‐Peytavi, Ulrike; Bohannon, Barbra; Bolognia, Jean; Bordeaux, Jeremy; Boyers, Lindsay; Brewer, Jerry; Camacho‐Martinez, Fra...
Journal:
British journal of dermatology
Issue:
Volume 172:Number 6(2015:Jun.)
Page Start:
1469
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Baricitinib 2 mg for the treatment of atopic dermatitis in North America: Long‐term efficacy and patient‐reported outcomes. Issue 12 (4th November 2022)

Authors:
Simpson, Eric; Armstrong, April; Boguniewicz, Mark; Chiesa Fuxench, Zelma C.; Feely, Meghan; Pierce, Evangeline; Sun, Luna; Chen, Yun‐Fei; Angle, Robinette; Silverberg, Jonathan I.
Journal:
Dermatologic therapy
Issue:
Volume 35:Issue 12(2022)
Page Start:
n/a
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. The time to offer treatments for COVID-19. (4th May 2021)

Authors:
Ngo, Binh T.; Marik, Paul; Kory, Pierre; Shapiro, Leland; Thomadsen, Raphael; Iglesias, Jose; Ditmore, Stephen; Rendell, Marc; Varon, Joseph; Dubé, Michael; Nanda, Neha; In, Gino; Arkfeld, Daniel; Chaudhary, Preet; Campese, Vito M.; Hanna, Diana L.; Sawcer, David E.; Ehresmann, Glenn; Peng, David...
Journal:
Expert opinion on investigational drugs
Issue:
Volume 30:Number 5(2021)
Page Start:
505
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗